TABLE 4.
Correlations between individual proms and covariates
| EQ‐5D‐5L | KCCQ scores | MDI | ||||||
|---|---|---|---|---|---|---|---|---|
| Utility | VAS | Physical limitation | Symptom frequency | Social limitation | Quality of life | Overall summary | Depression score | |
| Gender | 0.8822 | 0.5257 | 0.4600 | 0.5415 | 0.8084 | 0.1093 | 0.8353 | 0.8306 |
| Age category | 0.0458 | 0.0893 | 0.0213 | 0.1089 | 0.1704 | 0.1933 | 0.1157 | 0.2126 |
| Type of disease | 0.0871 | 0.8129 | 0.7566 | 0.1431 | 0.4015 | 0.4218 | 0.3577 | 0.3561 |
| Years since diagnosis | 0.0439 | 0.0299 | 0.1012 | 0.1453 | 0.1539 | 0.0385 | 0.0711 | 0.3116 |
| NYHA class | 0.0010/0.0114 | 0.0032/0.0383 | <.0001/0.0003 | <.0001/<.0001 | 0.0012/0.0139 | 0.0011/0.0134 | <.0001/<.0001 | 0.0003/0.0036 |
| NAC stage | 0.0164 | 0.0067 | 0.0284 | 0.0008/0.0096 | 0.0240 | 0.1917 | 0.0073 | 0.0210 |
| Treatment category | 0.2927 | 0.8990 | 0.0208 | 0.3541 | 0.1499 | 0.8514 | 0.1499 | 0.5854 |
| Diagnostic delay | 0.7844 | 0.0229 | 0.6645 | 0.0132 | 0.1275 | 0.0952 | 0.0668 | 0.1396 |
| Co‐morbidities | 0.0212 |
0.0010 /0.0094 |
0.0211 | 0.0185 | 0.0434 | 0.0174 | 0.0075 | 0.0822 |
P‐values for regression analyses for EQ‐5D‐5L, KCCQ and MDI according to covariates. Significant P‐values are indicated in bold, and P‐values that were still significant after Bonferroni correction are indicated in bold italics.
Covariate categories were as follows: Gender: Male/Female, Age category: <70 years/71–80 years/>81 years, Type of disease: hereditary ATTR CM/wildtype ATTR CM, Years since diagnosis: 0–5/over 5, NYHA class: NYHA I/NYHA II/NYHA III/NYHA IV, NAC stage: Stage 1/Stage 2/Stage 3, Treatment category: Symptomatic treatment/ATTR CM disease modifying treatment/The patient is participating in a randomized clinical trial, Diagnostic Delay: ≤1 year/>1 year, Co‐morbidities: Yes/No.
NYHA, New York Heart Association; NAC, National Amyloidosis Centre; KCCQ, Kansas City Cardiomyopathy Questionnaire; MDI, Major depression inventory; VAS, visual analogue scale.